CJC-1295 with DAC

CJC-1295 with DAC Peptide
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH). This modification was developed to improve stability and extend circulating half-life compared to native GHRH, potentially resulting in longer stimulation of growth hormone release. By binding to albumin in the bloodstream, the DAC component may reduce enzymatic degradation and renal clearance, thereby sustaining biological activity.

Overview
CJC-1295 with DAC is posited to exert its effects through the pituitary GHRH receptor, initiating downstream intracellular signaling that promotes pulsatile growth hormone secretion. Growth hormone, in turn, stimulates the systemic production of insulin-like growth factor-1 (IGF-1), considered a key mediator of anabolic activity, cellular growth, and repair. GH itself has been associated with lipolytic effects, including fat breakdown in visceral and abdominal depots. Research models indicate that the DAC modification allows CJC-1295 to maintain activity for days to weeks, unlike shorter-acting peptides.

It is hypothesized that CJC-1295 binding to the GHRH receptor may activate cyclic adenosine monophosphate (cAMP) pathways via adenylate cyclase stimulation, leading to protein kinase A (PKA) activation and phosphorylation of downstream targets. These cascades may contribute to the release of growth hormone from pituitary somatotroph cells. Studies suggest that this prolonged signaling may result in higher overall GH exposure and elevated IGF-1 levels compared to native GHRH analogs.

Chemical Information

• Appearance: White lyophilized powder
• Molecular Formula: C165H271N47O46
• Molecular Weight: ~3647.9 g/mol
• Sequence: Modified GHRH(1–29) with DAC attachment
• Purity (per COA): ≥ 98%

Stability and Storage
CJC-1295 with DAC is supplied as a lyophilized powder. For best results, it is recommended to store the product at –20°C. Reconstituted solutions should be handled under sterile conditions and kept at 2–8°C for short-term use.

Research and Clinical Studies

CJC-1295 with DAC and Growth Hormone Secretion
Early studies in human test subjects reported that a single administration of CJC-1295 with DAC produced measurable increases in both GH and IGF-1 lasting up to one week. This extended response contrasted with the rapid clearance of native GHRH analogs. Results suggested a 2–3 fold elevation in IGF-1, with consistent GH pulsatility maintained throughout the active period.

CJC-1295 with DAC and Metabolic Activity
Research indicates potential lipolytic effects due to enhanced GH exposure. In preclinical studies, elevated GH and IGF-1 levels were associated with improved fat metabolism and lean tissue preservation. The peptide has also been investigated for its potential to influence protein synthesis and tissue repair.

CJC-1295 with DAC and Half-Life Extension
Unlike shorter GHRH analogs, CJC-1295 DAC binds to albumin in circulation. This affinity is believed to reduce renal filtration and enzymatic degradation, significantly prolonging half-life. Reports suggest a terminal half-life of approximately 5.8 to 8.1 days, compared with minutes to hours for non-DAC peptides.

Stability and Storage
CJC-1295 with DAC peptide is provided as a lyophilized powder. For maximum stability, store at –20°C in a sealed container, protected from moisture and light. Following reconstitution, short-term storage at 2–8°C is recommended.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
   
2. Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9. https://pubmed.ncbi.nlm.nih.gov/19054601/
   
3. Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376. https://pubmed.ncbi.nlm.nih.gov/15814849/
   
4. Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14. https://pubmed.ncbi.nlm.nih.gov/29288913/
   
5. Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607. https://pubmed.ncbi.nlm.nih.gov/33281526/
   
6. Ranke MB, Wit JM. Growth hormone—past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300. https://pubmed.ncbi.nlm.nih.gov/29479014/
   
7. Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights. Eur J Endocrinol. 2021;185(6):R123-R136. https://pubmed.ncbi.nlm.nih.gov/34870144/
   
8. Smith TR, et al. The role of GH and IGF-1 in tissue repair and regeneration. Exp Gerontol. 2015;68:46-52. https://pubmed.ncbi.nlm.nih.gov/25987250/